Implant-based repair of osteochondral defects
10624987 ยท 2020-04-21
Assignee
Inventors
- Melissa A. Grunlan (College Station, TX, US)
- Mariah S. Hahn (Ballston Lake, NY, US)
- William B. Saunders (College Station, TX, US)
Cpc classification
A61L2300/412
HUMAN NECESSITIES
A61F2/30767
HUMAN NECESSITIES
A61L27/18
HUMAN NECESSITIES
A61L27/18
HUMAN NECESSITIES
A61F2002/30766
HUMAN NECESSITIES
A61L2430/02
HUMAN NECESSITIES
A61L27/16
HUMAN NECESSITIES
A61L2420/04
HUMAN NECESSITIES
A61L27/54
HUMAN NECESSITIES
International classification
A61L27/16
HUMAN NECESSITIES
A61L27/18
HUMAN NECESSITIES
A61L27/54
HUMAN NECESSITIES
Abstract
The present invention is directed to a unique technology for preparing a growth-factor free, cylindrical, hydrogel implant that has multiple (three or more) longitudinal hydrogel zones with varying chemical and physical properties. The implant may be wholly made of hydrogels or the hydrogels may be associated with cells, such as mesenchymal stem cells (MSCs).
Claims
1. A hydrogel implant comprising three or more hydrogel zones, wherein each hydrogel zone exhibits distinct tunable chemical and/or physical properties relative to one another and exhibits interpenetration between the adjacent hydrogel zones, and wherein the hydrogel zones comprise an inorganic polymer and an organic polymer wherein the inorganic polymer is methacrylated star polydimethylsiloxane and the organic polymer is diacrylated poly(ethylene glycol).
2. The hydrogel implant of claim 1, wherein the hydrogel implant is non-porated.
3. The hydrogel implant of claim 2, wherein a first hydrogel zone is fabricated from a first precursor solution comprising about 20:80 weight % ratio of inorganic polymer to organic polymer.
4. The hydrogel implant of claim 2, wherein a second hydrogel zone is fabricated from a second precursor solution comprising about 10:90 weight % ratio of inorganic polymer to organic polymer.
5. The hydrogel implant of claim 2, wherein a third hydrogel zone is fabricated from a third precursor solution comprising about 0:100 weight % ratio of inorganic polymer to organic polymer.
6. The hydrogel implant of claim 1, wherein the hydrogel implant is porated.
7. The hydrogel implant of claim 6, wherein a first hydrogel zone is fabricated from a first precursor solution comprising about 20:80 weight % ratio of inorganic polymer to organic polymer.
8. The hydrogel implant of claim 6, wherein a second hydrogel zone is fabricated from a second precursor solution comprising about 10:90 weight % ratio of inorganic polymer to organic polymer.
9. The hydrogel implant of claim 6, wherein a third hydrogel zone is fabricated from a third precursor solution comprising about 0:100 weight % ratio of inorganic polymer to organic polymer.
10. The hydrogel implant of claim 1, wherein the three or more hydrogel zones are at least one of discrete layers and continuous gradients of different compositions.
11. The hydrogel implant of claim 1, wherein at least one of the three or more hydrogel zones has a different porosity.
12. The hydrogel implant of claim 1, wherein the three or more hydrogel zones are a combination of non-porated and porated zones.
13. A method of preparing a hydrogel implant according to claim 1 comprising: preparing a first precursor solution comprised of about 20:80 weight % ratio of inorganic polymer to organic polymer; placing the first precursor solution layer within a cylindrical glass chamber; curing the first precursor solution layer to form a first hydrogel zone; preparing a second precursor solution comprised of a 10:90 weight % ratio of inorganic polymer to organic polymer 10 weight % in water; placing the second precursor solution layer within the cylindrical glass chamber over the first hydrogel zone; curing the second precursor solution layer to form a second hydrogel zone; preparing a third precursor solution comprised of a 0:100 weight % ratio of inorganic polymer to organic polymer; placing the third precursor solution layer within the cylindrical glass chamber over the first hydrogel zone; and curing the third precursor solution layer to form a third hydrogel zone, wherein the combination of the first hydrogel zone, the second hydrogel zone and the third hydrogel zone forms a hydrogel implant.
14. The method of claim 13, comprising adding additional hydrogel zones to the hydrogel implant by preparing additional precursor solutions, and sequentially placing the additional precursor solutions within the cylindrical glass chamber, over the top hydrogel zone of the hydrogel implant, and curing the additional precursor solution to form the additional hydrogel zone.
15. The method of claim 13, where the hydrogel implant is formed by placing the precursor solutions are cast over a poragen template placed within the cylindrical glass chamber, wherein the poragen template is comprised of salt, NaCI, CaCl.sub.2, RbCl.sub.2, paraffin, or sugar.
16. The method of claim 15, wherein the hydrogel implant is immersed in an aqueous solution to remove the poragen template prior to removing the hydrogel implant from the cylindrical glass chamber.
17. The method of claim 13, where each hydrogel zone is crosslinked to the adjacent hydrogel zone.
18. The method of claim 17, wherein the crosslinking is peformed using a chemical crosslinker.
19. The method of claim 17, wherein the crosslinking is performed using ultraviolet light.
20. A method for treating osteochondral defects in a subject, the method comprising: shaping the defect to accommodate a hydrogel implant according to claim 1 using arthroscopic techniques, implanting an autograft-sized, hydrogel implant, as determined by the arthroscopic technique used to shape the defect, providing structural support to the defect such that the hydrogel implant acts as support scaffolding and in the regeneration of the tissue types proximate to each hydrogel zone along the longitudinal axis of the hydrogel implant.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
DETAILED DESCRIPTION OF THE INVENTION
(5) In an embodiment of the invention, a poragen template is a template over which the hydrogel implant may be cast. Casting the hydrogel implant over the poragen template will result in pores forming within the hydrogel implant. The poragen may be salt (e.g. NaCl, CaCl.sub.2, RbCl.sub.2), sugar, paraffin or other particles. It is understood within the field of art that non-porated hydrogel zones will contain pores which are inherently present, based upon the nature of the hydrogel comprising the hydrogel zone. In this application, the term non-porated indicates that the pores are not being defined nor enlarged nor are the number of pores being increased, intentionally in a hydrogel zone via the use of a poragen template or other methods, above that which is inherently present following formation of the hydrogel zone. In addition, the term porated indicates that a pore size or pore size distribution was defined by use of a poragen during fabrication of the hydrogel zone.
(6) Each individual longitudinal hydrogel zone may be of varying length, and the length of each hydrogel zone would ideally parallel that of the adjacent native osteochondral tissue. Thus the length of each hydrogel zone will depend upon the thickness of the tissue that it spans. The hydrogel zones may be discrete layers or continuous gradients of different compositions. Between zones, some degree of interpenetration exists to integrate the zones and create soft interfaces. The implant may be a hydrogel comprised of a hydrophobic, inorganic polymer(s), within an organic polymer(s), distributed in spatially varied concentrations among hydrogel zones. Hydrogel zones with increasingly higher levels of inorganic polymer may generally be placed proximately to adjacent tissue regions with corresponding increasing osseous (i.e. bone-like) character.
(7) Due to its cylindrical geometry (i.e. resembling autograft plugs), the hydrogel implant may be placed within the osteochondral defect using conventional or arthroscopic surgery. Insertion of the implant is expected to occur by placement into a pre-drilled hole or holes formed in the defect site (i.e. where tissue damage has occurred). It is anticipated that a single implant would be inserted into a single pre-drilled holed. The individual implant may be prepared with essentially any size length and any size diameter, such that the implant could fit within the pre-drilled hole dimensions. This property (tunable length and diameter as well as corresponding zone lengths) allows for treatment of multiple animal species with varying sizes of osteochondral defects. Moreover, the composition of a given implant can be readily varied based on the defect size, animal species and desired cell behavior necessary for healing the various tissues. Alternatively, multiple implants of the same or different size may be inserted into a single pre-drilled hole. In
(8) In
(9)
(10) Alternately, these implants may be prepared in a non-cylindrical chamber. Subsequent to the hydrogel zones curing, a cylindrical shaped implant may be prepared by cutting a cylindrical implant using a die punch, either by hand or by a machine.
(11)
(12) One skilled in the art will appreciate that various polymers, macromers, monomers, crosslinkers and combinations may be used in preparation of the implant. Specific examples provided herein are examples only and should not be considered limiting.
WORKING EXAMPLES
(13) In the following specific examples, inorganic, methacrylated star polydimethylsiloxane (PDMS.sub.star-MA) and organic, diacrylated poly(ethylene glycol) (PEG-DA) are used to form the hydrogel implants. The PDMS.sub.star-MA component is osteoinductive (i.e. stimulating differentiation of multipotent cells into bone-forming lineages) and bioactive (i.e. promoting integration/bonding with surrounding bone tissue and the attachment & differentiation of osteogenic cells). In these examples, 3 hydrogel zones, of roughly equal height, are produced for each implant. The implants are formed by sequentially curing each layer using UV light, with or without a salt poragen template, in a cylindrical glass mold of a certain diameter and height. In this way, a cylindrical implant is formed with the corresponding hydrogel zones. In each example, a photocatalyst, (for example, 30 weight % solution of DMAP (4-Dimethylamino pyridine) in NVP (N-Vinylpyrrolidone) is used to accelerate UV-cure.
Example 1: 3 Hydrogel Zones; all Non-porated
(14) Water is used to form the precursor solutions. A salt template (i.e. poragen) is not used. The ratio of PDMS.sub.star-MA:PEG-DA is systematically increased from the 1.sup.st (bottom) to the 3.sup.rd (top) hydrogel zone (i.e. a relative decrease in PDMS.sub.star-MA from the bottom to top zone).
(15) The 1.sup.st (bottom) hydrogel zone is fabricated by the UV cure (30 sec) of a precursor solution layer comprised of a 20:80 weight % ratio of PDMS.sub.star-MA to PEG-DA (10 weight % in water). Next, the 2.sup.nd (middle) hydrogel zone is fabricated by the UV cure (30 sec) of a precursor solution layer comprised of a 10:90 weight % ratio of PDMS.sub.star-MA to PEG-DA (10 weight % in water) added on top of the first hydrogel zone. The 3.sup.rd (top) hydrogel zone is fabricated by the UV cure (30 sec) of a precursor solution layer comprised of a 0:100 weight % ratio of PDMS.sub.star-MA to PEG-DA (10 weight % in water) added on top of the middle hydrogel zone. In a final step, the implant is then exposed to UV light for another 2 minutes.
Example 2: 3 Hydrogel Zones; Porated
(16) Dichloromethane (DCM) is used to form the precursor solutions. A salt template is used in which average salt size decreases systematically from the 1.sup.st (bottom) to 3.sup.rd (top) hydrogel zone. The ratio of PDMS.sub.star-MA:PEG-DA is systematically increased from the 1.sup.st (bottom) to 3.sup.rd (top) hydrogel zone. Lastly, the salt template is removed via leaching in water to produce the final implant.
(17) For each hydrogel zone, a salt template (of a given hydrogel zone) is first created with the designated average salt size and fused with the addition of a small amount of water and optionally air dried. To this is added the designated precursor solution, the diffusion of which may be aided with centrifugation.
(18) The 1.sup.st (bottom) hydrogel zone is fabricated by the UV cure (30 sec) of a precursor solution layer comprised of a 20:80 weight % ratio of PDMS.sub.star-MA to PEG-DA (10 weight % in DCM). Next, the 2.sup.nd (middle) hydrogel zone is fabricated by the UV cure (30 sec) of a precursor solution layer comprised of a 10:90 weight % ratio of PDMS.sub.star-MA to PEG-DA (10 weight % in DCM) added on top of the bottom hydrogel zone. The 3.sup.rd (top) hydrogel zone is fabricated by the UV cure (30 sec) of a precursor solution layer comprised of a 0:100 weight % ratio of PDMS.sub.star-MA to PEG-DA (10 weight % in DCM) added on top of the middle hydrogel zone. In a final step, the implant is then exposed to UV light for another 2 minutes.
Example 3: 3 Hydrogel Zones; 2 Porated and 1 Non-porated
(19) Dichloromethane (DCM) is used to form the precursor solutions for the two porated hydrogel zones. A salt template is used in which average salt size varies systematically increased from the 1.sup.st (bottom) to 2.sup.nd (middle) hydrogel zone. For the 3.sup.rd (top) hydrogel zone, water is used to form the precursor solution and a salt template is not used. The ratio of PDMS.sub.star-MA:PEG-DA is systematically increased from the 1.sup.st (bottom) to the 3.sup.rd (top) hydrogel zone. Lastly, the salt template of the 1.sup.st (bottom) and 2.sup.nd (middle) is removed via leaching in water to produce the final implant.
(20) For the 1.sup.st (bottom) to 2.sup.nd (middle) hydrogel zone, a salt template (of a given hydrogel zone) is first created with the designated average salt size and fused with the addition of a small amount of water (so as to barely wet the salt) and then air dried. To this is added the designated precursor solution, the diffusion of which may be aided with centrifugation.
(21) The 1.sup.st (bottom) hydrogel zone is fabricated by the UV cure (30 sec) of a precursor solution layer comprised of a 20:80 weight % ratio of PDMS.sub.star-MA to PEG-DA (10 weight % in DCM). Next, the 2.sup.nd (middle) hydrogel zone is fabricated by the UV cure (30 sec) of a precursor solution layer comprised of a 10:90 weight % ratio of PDMS.sub.star-MA to PEG-DA (10 weight % in DCM) added on top of the 1.sup.st hydrogel zone. After formation of the porated 1.sup.st and 2.sup.nd hydrogel zones, the salt is leached into an aqueous solution. Next, the cylinder is transferred into the cylindrical mold. The 3.sup.rd (top) hydrogel zone is fabricated by the UV cure (30 sec) of a precursor solution layer comprised of a 0:100 weight % ratio of PDMS.sub.star-MA to PEG-DA (10 wt % in water) added on top of the middle hydrogel zone. In a final step, the implant is then exposed to UV light for another 2 minutes.
(22) While the present invention has been described in terms of certain preferred embodiments, it will be understood, of course, that the invention is not limited thereto since modifications may be made to those skilled in the art, particularly in light of the foregoing teachings.